This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Intracellularly expressed antibodies linked to the E3 ubiquitin ligase domain of STIP1 homology and U-box containing protein 1 (STUB1; CHIP) to enable targeted protein degradation	*In vitro* and cell culture studies suggest intracellular expression of antibodies linked to the E3 ubiquitin ligase domain of CHIP could promote ubiquitin-mediated degradation of target proteins. *In vitro*, an E3 ubiquitin ligase domain–linked single-chain variable fragment (scFv) specific for a model target protein caused ubiquitination of the protein. In cultured mammalian cells, plasmid-based expression of an E3 ubiquitin ligase domain–linked antibody-like protein led to degradation of a plasmid-expressed protein from *Escherichia coli*. Next steps include developing extracellular or transgenic delivery methods and testing the effect of the molecules, called ubiquibodies, on disease-associated proteins in cell culture. GlaxoSmithKline plc and Arvinas Inc. each have discovery stage programs to find small molecules that promote ubiquitin-mediated protein degradation. *SciBX* 7(7); doi:10.1038/scibx.2014.211 Published online Feb. 20, 2014	Patent pending; being licensed to Ubiquizyme Inc.	Portnoff, A.D. *et al. J. Biol. Chem.*; published online Jan. 28, 2014; doi:10.1074/jbc.M113.544825 **Contact:** Matthew P. DeLisa, Cornell University, Ithaca, N.Y. e-mail: md255@cornell.edu